SEATTLE--(Business Wire / Korea Newswire)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Taipei-based Prisma Biotech to broaden Parse’s reach in Taiwan and across Asia-Pacific.

“Biotech, pharma, and academic researchers across Asia are boosting demand for Parse’s Evercode single cell sequencing solutions in the region as they discover their scalability and simplicity,” noted Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. “We’re excited to empower them to easily take advantage of Parse’s single cell sequencing technology through our partnership with Prisma.”

The company’s agreement with Prisma Biotech will give a greater number of Asian researchers full access to Parse’s single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Select, CRISPR Detect, and the Parse Biosciences data analysis solution, Trailmaker. The agreement is a continuation of Parse’s ongoing market penetration in Asia, including South Korea, Singapore, and India, as well as in key international markets such as North America, Europe, Australia, Israel, and New Zealand.

“Single cell sequencing products are in high demand, and Parse’s Evercode technology is extremely compelling because of its scalability and ease of use,” noted Prisma Biotech CEO Kevin Tseng. “Our partnership with Parse will bring single cell sequencing to a wide range of researchers in Taiwan and the larger Asia-Pacific region, and we’re excited to support scientific discoveries the tools enable.”

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and a software tool for data analysis.

Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807623635/en/

Website: https://www.parsebiosciences.com/ Contact Parse Biosciences
Jay Roberts, SRPR
917.696.2142
[email protected]
This news is a press release provided by Parse Biosciences. Korea Newswire follows these editorial guidelines. Parse Biosciences News ReleasesSubscribeRSS 파스 바이오사이언스, 대만 프리즈마 바이오테크와 제휴해 아시아 지역 진출 확대 접근성이 뛰어나고 확장 가능한 단일 세포 시퀀싱 솔루션의 선도적 공급업체인 파스 바이오사이언스 (Parse Biosciences)는 타이베이에 본사를 둔 프리즈마 바이오텍 (Prisma Biotech)과 대만 및 아시아 태평양 지역에서 파스의 사업 범위를 확대하기 위한 협약을 체결했다고 발표했다. 파스 바이오사이언스의... 8월 9일 15:35 Parse Biosciences Launches Certified Service Provider Program Parse Biosciences , a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of its Certified Service Provider (CSP) Program. For researchers who are seeking paths to outsource their single cell projects, Parse’s CSP Program provides opt... 7월 12일 11:30 ... More  More News Health Biotechnology Alliance Overseas Parse Biosciences All News Releases 